Vertex Pharmaceuticals (NASDAQ: VRTX ... and investors who get in on the stock today should benefit for years to come. Let's ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Companies announce stock splits all the time, and so far this year a number of high profile companies have divvied up their ...

Vertex Pharmaceuticals continues to excel with strong Q3 results and promising clinical progress, but its valuation may ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its target price raised by research analysts at Scotiabank from ...

Shares of Vertex Pharmaceuticals Inc. VRTX rose 1.00% to $475.08 Wednesday, on what proved to be an all-around rough trading ...

Vertex Pharmaceuticals Inc. (VRTX) has disclosed a new risk, in the Innovation / R&D category. Vertex Pharmaceuticals Inc. faces ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Vertex Pharmaceuticals (VRTX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, VRTX broke through the 20-day moving average, which ...

Vertex (VRTX) delivered earnings and revenue surprises of 6.05% and 3.62%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Operator Good day, and welcome to the Vertex Pharmaceuticals third quarter 2024 earnings call. All participants will be in a ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price target boosted by analysts at Morgan Stanley from $473.00 to $476.00 in a note issued to investors on Tuesday, Benzinga reports.